In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant Keytruda (pembrolizumab).
Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.
